Key Takeaways
- UK-based Years recalls fresh dog meals due to reports of eye issues linked to possible buckwheat contamination.
- The FDA authorizes Simparica Trio to treat New World screwworm myiasis in dogs and puppies.
- Canine freeze-dried plasma (cFDP) offers a shelf-stable alternative to traditional frozen plasma for emergencies.
Pet Food Recall Amid Health Concerns
UK-based pet food manufacturer Years has announced a voluntary recall of all its fresh dog meals, except for the Chef’s Collection, following reports of dogs developing bilateral keratoconjunctivitis sicca (KCS), with some cases leading to sight loss. The company began receiving reports of potential eye issues in late July, accumulating 192 cases by August 18. Years is investigating buckwheat, recently added to its recipes, and has identified possible contamination in the buckwheat supply. However, a direct causation has not been confirmed. Symptoms of KCS include dry and irritated eyes, squinting, excessive blinking, and discharge. The company urges pet owners to cease feeding the recalled meals regardless of symptoms.
FDA’s Emergency Use Authorization
In another development, the FDA has granted an emergency use authorization (EUA) for Simparica Trio, a chewable tablet combining sarolaner, moxidectin, and pyrantel, specifically to treat New World screwworm myiasis in eligible dogs and puppies. This authorization tackles the treatment of the condition but does not extend to prevention. The chewable medication is available by prescription while the EUA is active. New World screwworm myiasis occurs when larvae feed on living tissue, typically after flies deposit eggs in open wounds, with signs including visible maggots and foul odors. The FDA reports that most dogs in the U.S. currently face low exposure risk, mainly in Texas and New Mexico. Veterinarians treating dogs from these areas or those who have traveled south are advised to remain vigilant.
Innovative Canine Plasma Solution
Lastly, canine freeze-dried plasma (cFDP) became commercially available in December 2025 following favorable FDA reviews. This shelf-stable plasma, derived from screened donor dogs, can be stored at room temperature and reconstituted for intravenous use. Unlike traditional frozen plasma, cFDP does not require freezing, making it more accessible in emergencies when blood banks are unavailable. Kelly Mann, DVM, MS, expressed that cFDP could find applications beyond military settings, aiding smaller clinics and veterinary trauma centers. This innovative product can serve as an initial plasma unit while further blood products are prepared.
The content above is a summary. For more details, see the source article.